News|Articles|February 10, 2023
SCOPE 2023: Challenging Operational Aspects of Clinical Trials
Author(s)Lisa Henderson
Len Rosenberg, head of clinical operations at Beat AML, reveals how changing the backbone treatment to a different regimen is beneficial to the patient, in terms of the safety with the same efficacy.
Advertisement
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Len Rosenberg, head of clinical operations at Beat AML, explains the operational obstacles that come with clinical trials, including background treatment dosages.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
2
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
3
Generative AI Transforms Clinical Study Report Development
4
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
